ARCHIVES

Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent

This article is from The Cancer Letter archive.

Vol. 34 No. 9 | September 30, 2011

Download PDF Visit The Full Archive

Related Articles

Huebner Retires, Named Scientist Emeritus

November 19, 1982

Prostatectomy Improves Outcome In Some Men

August 29, 2008

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

July 30, 2004

Letter to the Editors: Loss Of ET2 Would Be Disheartening, Member Of Study Section Says

February 20, 1998

Henderson Committee Final Recommendation Made On P01s

February 10, 1984

Center Directors, NCI Staff Agree- They Have Problems

November 26, 1976